MDT

99.8

-0.46%↓

147.83

+0.18%↑

VEEV

238.66

+0.24%↑

HQY

97.62

+2.79%↑

PHR.US

17.5

+1.74%↑

MDT

99.8

-0.46%↓

147.83

+0.18%↑

VEEV

238.66

+0.24%↑

HQY

97.62

+2.79%↑

PHR.US

17.5

+1.74%↑

MDT

99.8

-0.46%↓

147.83

+0.18%↑

VEEV

238.66

+0.24%↑

HQY

97.62

+2.79%↑

PHR.US

17.5

+1.74%↑

MDT

99.8

-0.46%↓

147.83

+0.18%↑

VEEV

238.66

+0.24%↑

HQY

97.62

+2.79%↑

PHR.US

17.5

+1.74%↑

MDT

99.8

-0.46%↓

147.83

+0.18%↑

VEEV

238.66

+0.24%↑

HQY

97.62

+2.79%↑

PHR.US

17.5

+1.74%↑

Accueil・Liste d'Actions・Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals Inc

Ouvert

SecteurSoins de santé

4.86 8.24

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

4.51

Max

4.89

Chiffres clés
By Trading Economics
Revenu	9.6M -162M
Ventes	-14M 5.2M
Marge bénéficiaire	-3,135.324
Employés	800
EBITDA	6.4M -141M

Recommandations
By TipRanks
Recommandations	Achat
Prévisions sur 12 Mois	+70.33% upside

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	-97M 2.3B
Ouverture précédente	-3.38
Clôture précédente	4.86

Sentiment de l'Actualité

By Acuity

50%

164 / 373 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Very Strong Bearish Evidence

4.15 / 4.75 Support & Résistance

Recursion Pharmaceuticals Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

6 janv. 2026, 21:14 UTC

Principaux Mouvements du Marché

Ventyx Biosciences Gains on Report of Possible $1 Billion Eli Lilly Deal

6 janv. 2026, 19:23 UTC

Acquisitions, Fusions, Rachats

OneStream to Go Private Through $6.4 Billion Hg Acquisition

6 janv. 2026, 17:41 UTC

Principaux Mouvements du Marché

Blink Charging Shares Rise as EV Chargers Begin Accepting Cryptocurrency

6 janv. 2026, 15:46 UTC

Acquisitions, Fusions, Rachats

Advent International Leads InPost Takeover Offer, Sky News Says

6 janv. 2026, 15:37 UTC

Principaux Mouvements du Marché

Terrestrial Energy Shares Rise After DOE Agreement For Nuclear Plant Development

6 janv. 2026, 23:46 UTC

Market Talk

Nikkei May Decline After Hitting Record High -- Market Talk

6 janv. 2026, 23:35 UTC

Market Talk

Gold Edges Higher Amid Ongoing Geopolitical Tensions -- Market Talk

6 janv. 2026, 23:19 UTC

Market Talk

Greatland 2Q Gold Output Strong, Sales Soft -- Market Talk

6 janv. 2026, 22:53 UTC

Market Talk

WiseTech, REA and CAR Look Best Insulated From AI Threat -- Market Talk

6 janv. 2026, 22:03 UTC

Acquisitions, Fusions, Rachats

Staar Surgical: Merger Proposal Received 14.9M Votes For and 27.3M Against

6 janv. 2026, 22:03 UTC

Acquisitions, Fusions, Rachats

Staar Surgical, Which Earlier Reported Stockholder Rejection of Sale to Alcon, Reports Vote Totals

6 janv. 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

6 janv. 2026, 21:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

6 janv. 2026, 21:12 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

6 janv. 2026, 21:12 UTC

Market Talk

Commodity Demand Helps Canada Reduce Reliance on Trade With U.S. -- Market Talk

6 janv. 2026, 20:59 UTC

Principaux Mouvements du Marché

Acquisitions, Fusions, Rachats

Ventyx Biosciences Gains on Report of Possible $1B Eli Lilly Deal

6 janv. 2026, 20:40 UTC

Acquisitions, Fusions, Rachats

Acquisition of Ventyx Would Bring Lilly Into Emerging Category of Pills for Inflammation-Related Conditions -- WSJ

6 janv. 2026, 20:40 UTC

Acquisitions, Fusions, Rachats

Eli Lilly Nears Deal for Biotech Ventyx -- WSJ

6 janv. 2026, 20:40 UTC

Acquisitions, Fusions, Rachats

Deal Could Be Announced Imminently, Sources Say -- WSJ

6 janv. 2026, 20:40 UTC

Acquisitions, Fusions, Rachats

Eli Lilly in Advanced Talks to Buy Ventyx Biosciences For Over $1B, Sources Say -- WSJ

6 janv. 2026, 20:01 UTC

Market Talk

Oil Futures Give Back Post-Venezuela Incursion Gains -- Market Talk

6 janv. 2026, 19:52 UTC

Market Talk

U.S. Natural Gas Falls Awaiting Colder Weather -- Market Talk

6 janv. 2026, 19:46 UTC

Acquisitions, Fusions, Rachats

Under Armour Stock Rises After the 'Warren Buffet of Canada' Boosts Its Stake -- Barrons.com

6 janv. 2026, 19:08 UTC

Acquisitions, Fusions, Rachats

OneStream to Go Private Through $6.4B Hg Acquisition

6 janv. 2026, 18:28 UTC

Acquisitions, Fusions, Rachats

These Stocks Are Moving the Most Today: Sandisk, Nvidia, AMD, Palantir, OneStream, SoFi, Microchip, and More -- Barrons.com

6 janv. 2026, 17:20 UTC

Market Talk

Résultats

Financial Services Roundup: Market Talk

6 janv. 2026, 17:20 UTC

Market Talk

Acquisitions, Fusions, Rachats

Health Care Roundup: Market Talk

6 janv. 2026, 15:57 UTC

Market Talk

Crude Futures Ease Back From Early Gains -- Market Talk

6 janv. 2026, 15:34 UTC

Market Talk

Résultats

Bank of Montreal Expects to Exit 2027 With ROE Hitting 15% Target -- Market Talk

6 janv. 2026, 15:27 UTC

Market Talk

German Inflation Won't Fall Much Further in 2026 -- Market Talk

Comparaison

Variation de prix

Recursion Pharmaceuticals Inc prévision

Objectif de Prix

By TipRanks

70.33% hausse

Prévisions sur 12 Mois

Moyen 7.75 USD 70.33%

Haut 11 USD

Bas 5 USD

Basé sur 6 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

6 ratings

Achat

Maintien

Vente

Basé sur 6 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Score Technique

By Trading Central

4.15 / 4.75Support & Résistance

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

All events are bearish.

Sentiment

By Acuity

164 / 373Classement par Soins de santé

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.